Search results for "From ACP Journal Club"
In high-risk pregnant women, an individualized lifestyle intervention reduced gestational diabetes mellitus
The intervention in the Finnish study targeted women with previous gestational diabetes mellitus or a body mass index of 30 kg/m2 or greater.
https://diabetes.acponline.org/archives/2016/01/08/5.htm
8 Jan 2016
In acute ischemic stroke with hyperglycemia, intensive vs standard glucose control did not improve 90-day outcomes
Several factors, including high rates of reperfusion therapy and early hospital discharge, may explain why this trial found no benefit from intensive glucose control after stroke, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/01/10/7.htm
10 Jan 2020
In metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels
Patients whose diabetes was inadequately controlled on metformin showed similar weight loss, improvement in HbA1c, and adverse events whether they took dulaglutide or liraglutide, a trial found.
https://diabetes.acponline.org/archives/2014/12/12/6.htm
12 Dec 2014
Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria
In a trial of more than 1,000 diabetic patients with proteinuria, adding an ACE inhibitor to an ARB didn't improve estimated glomerular filtration rate and increased risk for hyperkalemia and acute kidney injury, so the trial was halted early.
https://diabetes.acponline.org/archives/2014/05/09/6.htm
9 May 2014
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/11/08/7.htm
8 Nov 2019
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017
Continuous glucose monitoring reduced hypoglycemia over 6 months
The positive results of a trial of continuous glucose monitoring in type 1 diabetes patients ages 60 years and older support recommending the technology to this group, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/12/11/10.htm
11 Dec 2020
In newly diagnosed type 2 diabetes mellitus, a Mediterranean diet (vs. a low-fat diet) delayed start of glucose-lowering drugs
Patients who were randomized to a low-carbohydrate Mediterranean diet shortly after type 2 diabetes diagnosis delayed their need for medication compared to those put on a low-fat diet in an Italian trial.
https://diabetes.acponline.org/archives/2014/10/10/5.htm
10 Oct 2014
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
Sodium–glucose cotransporter 2 inhibitors appear to be a promising treatment option for patients with diabetes and chronic kidney disease, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/6.htm
13 Sep 2019
Incretin use was not associated with increased risk for acute pancreatitis
Patients who took incretin-based drugs had the same risk of acute pancreatitis as those who took other hypoglycemic medications or took neither type of drug, a case-control study found.
https://diabetes.acponline.org/archives/2015/07/10/6.htm
10 Jul 2015